Muc16-directed CAR-T cells engineered to express CCR2, the cognate receptor to CCL2, demonstrate better in vitro and in vivo tumor-directed trafficking and improve survival in tumor-bearing mice. This evidence concerns the gene CCL2 and neoplasm.